The AMA CPT Editorial Panel approved a Category I code for implanting a subfascial tibial neuromodulation device, BlueWind Medical said on October 2. The code takes effect January 1, 2028. A separate Category I code covers subcutaneous implantation, the approach behind Medtronic's Altaviva and Valencia Technologies' eCoin.
BlueWind's Revi puts a miniature implant near the ankle and powers it with an external wearable, with a design life of 15 years and no battery replacement. FDA granted it a De Novo in 2023 for urgency urinary incontinence. The company reports 79 percent efficacy at three years and 95 percent patient satisfaction, with implantation done in an outpatient setting under local anesthesia. Urologists will next complete an AMA RUC survey that feeds the Medicare payment valuation.
Getting off a Category III tracking code is what separates a procedure payers will price from one they treat as investigational, and splitting subfascial from subcutaneous means claims data will finally tell the two approaches apart. The catch is the calendar. A code approved in late 2026 pays nothing until 2028, so anyone modeling revenue off this needs 15 more months of runway in the plan.